Institut du Fer à Moulin. Paris, France
Primary cilium-dependent cortical interneuron migration in Down Syndrome mouse models
Financing: Fondation Lejeune
Institut du Cerveau et de la Moelle Epinière. Paris, France
Elucidating the effects of age-related and tissue-specific modulation of DYRK1A expression on Alzheimer’s disease-like pathology in mice
Financing: Fondation Lejeune
Centre for Genomic Regulation. Barcelona, Spain
Stratifying Cognitive Improvements to Reveal the Effect of Allelic Diversity in Trisomy 21
Financing: Fondation Lejeune
Monash University. Clayton, Australia
Understanding how gene interactions in Down syndrome impacts cognitive decline; structure to function relationships in brains
Financing: Fondation Lejeune
University of Naples Federico II. Naples, Italy
Defects in mitophagy and mitochondrial activity as key determinants of Alzheimer’s disease in Down Syndrome: novel therapeutic strategies
Financing: Fondation Lejeune
Fondazione Istituto Italiano di Tecnologia. Genova, Italy
Early NKCC1 Inhibition to treat epilepsy and hyperactivity in Down syndrome
Financing: Fondation Lejeune
KU Leuven. Leuven, Belgium
Cardiopulmonary-vascular disorders in Down syndrome research: a long-overlooked issue
Financing: Fondation Lejeune
University of Queensland. Brisbane, Australia
Elucidating the genetic drivers of accelerated cellular ageing in Down syndrome
Financing: Fondation Lejeune
University of Western Australia. Perth, Australia
Down syndrome-Acute lymphoblastic leukaemia (DS-ALL): A model to unravel the molecular mechanisms underlying treatment-resistance in paediatric leukaemia »
Co-financing: Fondation Sisley-D’Ornano and Fondation Lejeune
Blizzard Institute. Queen Mary University of London. London, United Kingdom
Assessment of specific biological features of trisomy 21 neurons, affecting cell-cell transmission of Alzheimer’s pathology using cerebral organoids
Financing: Fondation Lejeune
Institut du Cerveau et de la Moelle Epinière. Paris, France
Role of PFC SST+ interneurons on emotional state recognition in a mouse model of Down syndrome
Financing: Fondation Lejeune
Institut du Cerveau et de la Moelle Epinière. Paris, France
Uncovering the signaling pathways to neurodegeneration of the locus coerulus, and cognitive impairments in Down syndrome
Co-financing: Fondation Sisley-D’Ornano and Fondation Lejeune
Stanford University. Stanford, United States
Usp16 as a new therapeutic target in Alzheimer disease and Down syndrome
Financing: Fondation Lejeune
Institut de Génétique et de Biologie Moléculaire et Cellulaire. Illkirch, France
Role of DYRK1A in GABAergic inhibitory neurons development, impact on the excitatory/inhibitory balance in diseases with intellectual disabilities
Co-financing: Fondation Sisley-D’Ornano and Fondation Lejeune
Hospital de la Santa Creu i Sant Pau. Barcelona, Spain
Discovery of novel biomarkers signaling NGF metabolic dysfunction and early AD-dementia in Down syndrome
Financing: Fondation Lejeune
Life and health science research institute. University of Minho. Braga, Portugal
Tau therapeutics in Down syndrome & Alzheimer’s disease brain pathologies
Co-financing: Fondation Sisley-D’Ornano and Fondation Lejeune